A report from GHTC and Policy Cures Research examines how US federal funding for global health R&D is delivering impact both abroad and at home.

Search the GHTC website

Leading with science, we can end the AIDS pandemic

Read time:
PATH

December 1 marks the commemoration of World AIDS Day—a day to reflect on an epidemic that has affected millions of lives worldwide for three decades now and how far we’ve come towards an end. This year’s focus and theme is a right on target: “Leading with Science, United for Action.”

November 30, 2011 by Nelson Michael

Nelson L. Michael, M.D., Ph.D is the Director of the U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR), an international HIV vaccine research program that successfully integrates HIV and AIDS prevention, care and treatment. In this post, Col. Michael reflects on the progress being made in HIV prevention science.

December 1 marks the commemoration of World AIDS Day—a day to reflect on an epidemic that has affected millions of lives worldwide for three decades now and how far we’ve come towards an end. This year’s focus and theme is a right on target: “Leading with Science, United for Action.”

Recent scientific achievements have brought us closer to eliminating AIDS than we have ever been. Results from the landmark RV144 trial, an international collaboration that involved more than 16,000 Thai volunteers, were announced in 2009. While it took a quarter of the century from the discovery of HIV to show that a vaccine is possible, the results of RV144—which showed the first scientific evidence of vaccine efficacy—have propelled the HIV vaccine research field forward.

Earlier this year, we announced the results of extensive follow-up laboratory studies that provide new clues about the types of immune responses that may have played a role in the protection seen in RV144. These new advances were the result of nearly two years of work by more than 100 researchers at 25 institutions worldwide. We now have a better understanding of how the vaccine may have prevented infection and a renewed scientific direction to help guide future vaccine development.

We are united in our efforts to end AIDS; no one organization can do it alone. As we move forward, MHRP’s collaborators are leading a tremendous effort to identify correlates of protection. Additionally, a new collaboration—a public-private partnership called P5 that comprises MHRP, the Division of AIDS/NIAID, the Bill and Melinda Gates Foundation, Sanofi Pasteur, Novartis, and the HIV Vaccine Trials Network—is planning the next set of Phase IIb trials to build on the results of RV144 and bring us closer to a vaccine product with a public health impact.

MHRP’s commitment to ending AIDS extends beyond developing an efficacious vaccine to creating innovative programs to prevent and treat HIV through the President’s Emergency Plan for AIDS Relief (PEPFAR). In 2011, our site in Uganda, the Makerere University Walter Reed Program launched the first ever mobile circumcision clinic with the ambitious goal to circumcise 6,000 men by year’s end, Kenya has become a leader in the prevention of mother-to-child transmission (PMTCT) due in large part to the efforts of the Walter Reed Project, and the number of patients currently receiving antiretroviral therapy at all of MHRP’s African sites—Kenya, Nigeria, Tanzania and Uganda—exceeded 100,000.

A world without AIDS seems more achievable now than any other time in history. However, one prevention strategy alone will not be the end all to this pandemic. We must maintain the momentum and commitment to both scaling up currently available and evidence-based prevention strategies and finding a long-term solution to eliminate AIDS. In the meantime, MHRP is uniquely positioned to move HIV vaccine science forward and to inform HIV prevention, care and treatment with scientific data to develop best practices and to ensure the best, most efficient practices are provided around the globe.

Categories: DoD, Guest post, HIV/AIDS

About the author

Nelson MichaelWalter Reed Army Institute of Research

Nelson Michael is the Director the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research.

Other Breakthroughs Blog posts you may like:
USAID/Alex Kamweru
November 11, 2024

Research Roundup: First-of-its-kind mpox vaccine trial, New treatment-resistant malaria drug, Genetically modified mosquitos

Written by Hannah Sachs-Wetstone / GHTC
Read time:
Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email. A new, first-of-its-kind trial will assess the safety and immunogenicity of Bavarian Nordic’s MVA-BN mpox vaccine in pregnant and breastfeeding women and infants under two years old, two populations at risk of severe complications from mpox but not currently eligible for vaccination. MVA-BN is the only vaccine for mpox prequalified by the World Health Organization and is currently approved for healthy adults and adolescents, but additional data from this trial could help expand access for additional key populations amid the ongoing mpox outbreak. The trial, which will start early next year, is jointly funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and Global Health EDCTP3.Researchers from the University of Glasgow have developed a new drug that could help combat the spread of treatment-resistant malaria, as the disease continues to kill more than 600,000 people every year and Plasmodium falciparum, a mosquito vector that spreads malaria, grows increasingly resistant to artemisinin, the frontline malaria treatment. The drug, adapted from a cancer treatment approach, works by permanently disabling a protein that P. falciparum uses to duplicate itself in humans. The researchers behind the drug think it could be more effective than current drugs at all stages of malaria infection, potentially with only one dose.A research team from the University of California, Santa Barbara has found a way to potentially reduce the spread of mosquito-borne diseases by disrupting male mosquitoes’ ability to hear, which is essential for them to mate and breed. Male mosquitoes rely on the sound of female mosquitoes’ wingbeats in order to find and mate with them. By altering a genetic pathway that male mosquitoes use for hearing, the researchers were able to stop them mating entirely, preventing female mosquitoes, the ones that spread diseases to humans, from having babies and reducing overall mosquito populations. Specifically, the researchers studied Aedes aegypti mosquitoes, which spread diseases including dengue, yellow fever, and Zika.
PATH/Enoch Kavindele Jr.
November 4, 2024

Research Roundup: Noninvasive malaria test, Mpox vaccine trial for kids, Novel class of antimicrobial agents

Written by Hannah Sachs-Wetstone / GHTC
Read time:
Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email. Recently published research found that a new, noninvasive test for malaria could provide a more reliable, safer, quicker, and more sensitive diagnostic option in low- and middle-income countries. The Cytophone, a tabletop printer-sized device, uses targeted lasers and ultrasound to detect malaria-infected cells in the bloodstream via a small, noninvasive probe placed on the back of a person’s hand. Malaria-infected red blood cells accumulate a by-product with unique properties that can be distinguished from normal red blood cells when they pass through a laser. The test, which provides results within minutes, was found to be as good or better at detecting symptomatic Plasmodium falciparum malaria infections than the current gold standard point-of-care methods for malaria testing, which require blood samples and special laboratory equipment. The next phase of testing the device will also investigate whether the device can detect and distinguish between other species.Last Tuesday, Bavarian Nordic announced the start of a clinical study of the MVA-BN® mpox/smallpox vaccine in children between 2 and 11 years old, who are highly vulnerable to infection during the ongoing mpox emergency. The study, which currently has sites in the Democratic Republic of Congo and plans to include sites in Uganda as well, is investigating the safety and immunogenicity of the vaccine in children compared to adults. Last month, the World Health Organization prequalified the vaccine for adolescents between 12 and 17 years old, following the European Medicines Agency’s approval for this age group. Results from the new trial could support an extension of the current approval.Researchers have identified a novel class of antimicrobial agents known as encrypted peptides that play a key role in the immune system’s response to bacterial infections, opening up new possibilities for combating drug-resistant infections as antimicrobial resistance continues to grow as a global health threat. The immune system is traditionally thought to rely primarily on proteins explicitly linked to immune functions, but this new research reveals that other structural proteins contribute to antimicrobial defenses. Leveraging the immune system’s natural defenses through these non-immune proteins could allow researchers to develop effective antibiotic therapies less prone to resistance.